US · PTGX · BIOTECHNOLOGY
Protagonist Therapeutics, Inc. (PTGX) intrinsic value and stock valuation
$121.40as of 2026-11-21 · Mkt cap 9.38B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Protagonist Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values PTGX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from PTGX’s statements →
Protagonist Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $46M | $434.4M | $60M | $26.6M | $27.4M |
| Operating income | -$-158.13M | $252.8M | -$-93.65M | -$-131.37M | -$-125.84M |
| Net income | -$-130.15M | $275.2M | -$-78.95M | -$-127.39M | -$-125.55M |
| EPSd | -$-2.05M | $4.23M | -$-1.39M | -$-2.6M | -$-2.71M |
| Operating cash flow | $57.7M | $184.2M | -$-70.24M | -$-108.14M | -$-107.86M |
| Capital expenditure | -$-1.59M | -$-1.35M | -$-610K | -$-800K | -$-1.1M |
| Free cash flow | $56.1M | $182.8M | -$-70.84M | -$-108.93M | -$-108.97M |
| Total assets | $669.9M | $744.7M | $358M | $247.9M | $347.7M |
| Total debt | $10.3M | $10.9M | $1.14M | $3.66M | $5.86M |
| Net debt | -$-118.07M | -$-86.38M | -$-185.59M | -$-122.09M | -$-117.81M |
| Total equity | $614.7M | $675.3M | $336.7M | $215.6M | $300M |
| Cash and short-term investments | $567.4M | $418.9M | $341.6M | $237.4M | $326.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $46M | $434.4M | $60M | $26.6M | $27.4M |
| Cost of revenue | $1.23M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $44.8M | $434.4M | $60M | $26.6M | $27.4M |
| Research and development expenses | $159.3M | $138.1M | $120.2M | $126.2M | $126M |
| Selling, general and administrative expenses | $44.9M | $43.5M | $33.5M | $31.7M | $27.2M |
| Other expenses | -$-1.23M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $202.9M | $181.6M | $153.7M | $158M | $153.2M |
| Cost and expenses | $204.1M | $181.6M | $153.7M | $158M | $153.2M |
| Interest income | $28.8M | $26.3M | $14.9M | $4.06M | $440K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.23M | $830K | $3.31M | $3.37M | $2.77M |
| Ebitda | -$-128.09M | $280.2M | -$-75.64M | -$-124.02M | -$-122.78M |
| Operating income | -$-158.13M | $252.8M | -$-93.65M | -$-131.37M | -$-125.84M |
| Total other income/expenses, net | $28.8M | $26.6M | $14.7M | $3.98M | $290K |
| Income before tax | -$-129.31M | $279.4M | -$-78.95M | -$-127.39M | -$-125.55M |
| Income tax expense | $840K | $4.22M | $0.00 | $0.00 | $0.00 |
| Net income | -$-130.15M | $275.2M | -$-78.95M | -$-127.39M | -$-125.55M |
| Weighted average shares outstanding | $63.6M | $61.6M | $56.8M | $49M | $46.3M |
| Weighted average diluted shares outstanding | $63.6M | $65.1M | $56.8M | $49M | $46.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $567.4M | $418.9M | $341.6M | $237.4M | $326.9M |
| Net receivables | $4.5M | $168.5M | $10.3M | $50K | $5.33M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $577.6M | $591.6M | $355.6M | $243.1M | $340.7M |
| Property, plant and equipment, net | $11.7M | $12.6M | $2.15M | $4.63M | $6.73M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $78.9M | $140.3M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $92.3M | $153.1M | $2.37M | $4.85M | $6.96M |
| Total assets | $669.9M | $744.7M | $358M | $247.9M | $347.7M |
| Accounts payable | $5.34M | $1.61M | $770K | $3.64M | $1.6M |
| Short-term debt | $2.28M | $510K | $1.14M | $2.52M | $2.2M |
| Deferred revenue | $9.55M | $18.9M | $0.00 | $70K | $2.5M |
| Total current liabilities | $45.4M | $47.4M | $21.3M | $31.2M | $44M |
| Long-term debt | $8.04M | $10.4M | $0.00 | $1.14M | $3.66M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $9.74M | $22M | $0.00 | $1.14M | $3.66M |
| Capital lease obligations | $8.04M | $10.4M | $1.14M | $3.66M | $5.86M |
| Total liabilities | $55.2M | $69.4M | $21.3M | $32.3M | $47.7M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-470.67M | -$-340.52M | -$-615.71M | -$-536.75M | -$-409.36M |
| Accumulated other comprehensive income (loss) | $640K | -$-80K | -$-100K | -$-360K | -$-300K |
| Total equity | $614.7M | $675.3M | $336.7M | $215.6M | $300M |
| Total investments | $517.9M | $461.9M | $154.9M | $111.6M | $203.2M |
| Total debt | $10.3M | $10.9M | $1.14M | $3.66M | $5.86M |
| Net debt | -$-118.07M | -$-86.38M | -$-185.59M | -$-122.09M | -$-117.81M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-130.15M | $275.2M | -$-78.95M | -$-127.39M | -$-125.55M |
| Depreciation and amortization | $1.28M | $2.9M | $3.31M | $3.37M | $2.77M |
| Stock-based compensation | $46M | $37.6M | $29.3M | $24.2M | $16.4M |
| Change in working capital | $146.2M | -$-122.61M | -$-19.51M | -$-7.77M | -$-3.31M |
| Accounts receivable | $164.9M | -$-155M | -$-9.99M | $4.24M | -$-920K |
| Inventory | $0.00 | $0.00 | $0.00 | -$-4.24M | $920K |
| Accounts payable | $3.72M | $840K | -$-2.87M | $2.04M | -$-1.39M |
| Net cash provided by operating activities | $57.7M | $184.2M | -$-70.24M | -$-108.14M | -$-107.86M |
| Investments in property, plant and equipment | -$-1.59M | -$-1.35M | -$-610K | -$-800K | -$-1.1M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-91.47M | $14.8M |
| Net cash used for investing activities | -$-49.33M | -$-299.48M | -$-39.26M | $91.5M | -$-15.86M |
| Common stock issued | $23.3M | $26.5M | $132.1M | $14.6M | $123.8M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $22.9M | $25.9M | $170.5M | $18.8M | $129.9M |
| Net change in cash | $31.1M | -$-89.48M | $61M | $2.08M | $6.07M |
| Cash at end of period | $128.4M | $97.5M | $187M | $126M | $123.9M |
| Operating cash flow | $57.7M | $184.2M | -$-70.24M | -$-108.14M | -$-107.86M |
| Capital expenditure | -$-1.59M | -$-1.35M | -$-610K | -$-800K | -$-1.1M |
| Free cash flow | $56.1M | $182.8M | -$-70.84M | -$-108.93M | -$-108.97M |
Line items
Line items
Line items
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
- CEO
- Dinesh V. Patel
- Employees
- 132
- Beta
- 1.79
Explore
Frequently asked questions
What is the intrinsic value of Protagonist Therapeutics, Inc. (PTGX)?
Protagonist Therapeutics, Inc. (PTGX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PTGX undervalued?
PTGX trades at a price of $121.40 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.